Hikma Pharmaceuticals PLC - Back to Homepage

Keep yourself updated about Hikma

News Search

Search for a news item according to period of time or category.

Ensuring the Sustainability of our Business

Download Hikma's latest CR Report

13 October 2014

Hikma enters partnership with Eisai for distribution of first-in-class epilepsy treatment Fycompa® in Middle East

London, 13 October 2014– Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announces a partnership with Eisai Co., Ltd. (“Eisai”) for the distribution of Fycompa® (perampanel), Eisai’s first-in-class epilepsy treatment, in the Middle East. The partnership will commence immediately, with perampanel launches throughout the region expected to follow in 2015. Perampanel is indicated for the adjunctive treatment of partial onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 years and older.i

London, 13 October 2014 - Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announces a partnership with Eisai Co., Ltd. (“Eisai”) for the distribution of Fycompa® (perampanel), Eisai’s first-in-class epilepsy treatment, in the Middle East. The partnership will commence immediately, with perampanel launches throughout the region expected to follow in 2015. Perampanel is indicated for the adjunctive treatment of partial onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 years and older.i

Perampanel is the only licensed anti-epileptic drug (AED) to selectively target AMPA receptors, a protein in the brain which plays a critical role in the spread of seizures.ii This mechanism of action is different to other currently available AEDs. In addition, perampanel has the added benefit of convenient, once-daily dosing at bedtime.i

“We are committed to our partnership with Eisai, which supports our strategy of working with global partners to strengthen our product portfolio in growing therapeutic areas and to bring important treatment options to patients in the Middle East region,” commented Mazen Darwazah, Hikma Pharmaceutical’s Executive Vice Chairman and President and CEO of MENA and Emerging Markets.

“We are very pleased to announce the partnership with Hikma, who will leverage their strong presence in the Middle East to ensure that people throughout the region will soon be able to access our innovative epilepsy treatment Fycompa,” commented Gary Hendler, President & CEO, Eisai EMEA.

Epilepsy is one of the most common neurological conditions in the world.iii The successful treatment of partial onset seizures remains a significant challenge in some patients and the incidence of uncontrolled partial epilepsy remains high despite many AEDs. Currently, up to 40% of patients with newly diagnosed epilepsy will become refractory to treatment.iv

Countries covered by the five year partnership will include the Kingdom of Saudi Arabia, United Arab Emirates, Jordan, Kuwait, Bahrain, Oman, Qatar, Sudan, Iraq, Libya and Yemen. Perampanel was approved by the European Commission on 23 July 2012 and the United States Federal Drug Administration (FDA) on 22 October 2012. Discovered and developed by Eisai in Europe and Japan, perampanel is manufactured in the UK.

-- ENDS --

Enquiries:

Hikma Pharmaceuticals PLC  
Susan Ringdal, VP Corporate Strategy and Director of Investor Relations +44 (0)20 7399 2760
Lucinda Henderson, Deputy Investor Relations Director +44 (0)20 7399 2765
FTI Consulting
Ben Atwell/ Matthew Cole/ Julia Phillips +44 (0)20 3727 1000

 

About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: “Branded”, “Injectables” and “Generics”, based principally in the Middle East and North Africa ("MENA"), where it is a market leader, the United States and Europe. In 2013, Hikma achieved revenues of $1,365 million and profit attributable to shareholders of $212 million.

Press Release
+ more
Print page

Product

08 October 2014

Hikma awarded Global Generics Company of the Year for EMEA

London, 8 October 2014 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group is pleased to announce that it was the recipient of the ‘Company of the Year, EMEA Award” at the Global Generics and Biosimilars Awards held in Paris on 7 October 2014.

London, 8 October 2014 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group is pleased to announce that it was the recipient of the ‘Company of the Year, EMEA Award” at the Global Generics and Biosimilars Awards held in Paris on 7 October 2014. The award recognises excellent performance across a range of business activities and was won in strong competition against a number of leading EMEA pharmaceutical companies.

-- ENDS --

Enquiries:

Hikma Pharmaceuticals PLC  
Susan Ringdal, VP Corporate Strategy and Director of Investor Relations +44 (0)20 7399 2760
FTI Consulting
Ben Atwell/ Matthew Cole/ Julia Phillips +44 (0)20 7831 3113

About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma operates through three businesses: “Branded”, “Injectables” and “Generics”, based principally in the Middle East and North Africa ("MENA"), where it is a market leader, the United States and Europe.  In 2013, Hikma achieved revenues of $1,365 million and profit attributable to shareholders of $212 million.

Press Release
+ more
Print page

Corporate

30 September 2014

Hikma receives approval for colchicine 0.6mg capsules

London, 30 September 2014 – Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announces the approval of its New Drug Application (NDA) for colchicine 0.6mg capsules by the US Food and Drug Administration (FDA).

London, 30 September 2014 – Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announces the approval of its New Drug Application (NDA) for colchicine 0.6mg capsules by the US Food and Drug Administration (FDA). Hikma will market its colchicine under the brand name MITIGARE.

MITIGARE is indicated for prophylaxis of gout flares in adults. This NDA has been approved under Section 505(b)(2) of the US Federal Food Drug and Cosmetic Act.

Said Darwazah, Chairman and CEO of Hikma, said, "This approval demonstrates our strong regulatory capabilities and the successful execution of our strategy to develop a more differentiated product portfolio for the US market."

According to IMS Health, sales of colchicine in the US market were approximately $688 million for the 12 months ending August 2014.

-- ENDS --

Enquiries:

Hikma Pharmaceuticals PLC  
Susan Ringdal, VP Corporate Strategy and Investor Relations +44 (0)20 7399 2760/
+44 7776 477050
Lucinda Henderson, Deputy Director of Investor Relations +44 (0)20 7399 2765/
+44 7818 060211
FTI Consulting
Ben Atwell/ Matthew Cole/ Julia Phillips +44 (0)20 7831 3113

About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: "Branded", "Injectables" and "Generics", based principally in the Middle East and North Africa ("MENA"), where it is a market leader, the United States and Europe. In 2013, Hikma achieved revenues of $1,365 million and profit attributable to shareholders of $212 million.

Press Release
+ more
Print page

Corporate

29 September 2014

Hikma Meet the Management Day

London, 29 September 2014 – Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK), the fast growing multinational pharmaceutical group, will host a Meet the Management Day in London on Tuesday 2 December 2014.

London, 29 September 2014 – Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK), the fast growing multinational pharmaceutical group, will host a Meet the Management Day in London on Tuesday 2 December 2014.

If you are interested in attending this event please contact Kate Komornicka kate@hikma.uk.com to register your interest and for further details.

-- ENDS --

Enquiries:

Hikma Pharmaceuticals PLC  
Susan Ringdal, VP Corporate Strategy and Investor Relations +44 (0)20 7399 2760/
+44 7776 477050
Lucinda Henderson, Deputy Head of Investor Relations +44 (0)20 7399 2765/
+44 7818 060211
FTI Consulting
Ben Atwell/ Matthew Cole/ Julia Phillips +44 (0)20 3727 1000

 

About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: “Branded”, “Injectables” and “Generics”, based principally in the Middle East and North Africa ("MENA"), where it is a market leader, the United States and Europe. In 2013, Hikma achieved revenues of $1,365 million and profit attributable to shareholders of $212 million.

Press Release
+ more
Print page

Corporate

17 September 2014

Hikma completes acquisition of Ben Venue manufacturing site

London, 17 September 2014 – Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announces that it has completed its acquisition of substantially all of the assets of the generic injectables manufacturing site of Ben Venue Laboratories, Inc. ("Ben Venue"), part of the Boehringer Ingelheim Group of Companies, as agreed on 24 July 2014.

London, 17 September 2014 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announces that it has completed its acquisition of substantially all of the assets of the generic injectables manufacturing site of Ben Venue Laboratories, Inc. ("Ben Venue"), part of the Boehringer Ingelheim Group of Companies, as agreed on 24 July 2014.

The Ben Venue site includes four manufacturing plants and a state-of-the-art Quality and Development Centre ("QDC"). The QDC, which includes a R&D pilot plant, will significantly strengthen Hikma's existing R&D capabilities and support the development of a strong future pipeline. The four manufacturing plants are not currently in use. Hikma will transfer certain modern, advanced equipment to significantly increase capacity at its other manufacturing facilities in the United States and Europe.

Said Darwazah, Chairman and Chief Executive Officer of Hikma commented:

"I am very pleased to be acquiring the Ben Venue manufacturing site, which will significantly enhance our R&D capabilities and enable us to expand future capacity. This reflects our commitment to the long term growth of our global Injectables business and will create significant strategic value."

-- ENDS --

Enquiries:

Hikma Pharmaceuticals PLC  
Susan Ringd al, VP Corporate Strategy and Director of Investor Relations +44 (0)20 7399 2760/
+44 7776 477050
Lucinda Henderson, Deputy Director of Investor Relations +44 (0)20 7399 2765/
+44 7818 060211
FTI Consulting
Ben Atwell/ Matthew Cole/ Julia Phillips +44 (0)20 3727 1000

 

About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: "Branded", "Injectables" and "Generics", based principally in the Middle East and North Africa ("MENA"), where it is a market leader, the United States and Europe. In 2013, Hikma achieved revenues of $1,365 million and profit attributable to shareholders of $212 million.

Press Release
+ more
Print page

Corporate

20 August 2014

Hikma Pharmaceuticals Interim Results

Hikma delivers excellent first half results with 16% revenue growth and 44% increase in adjusted EPS

London, 20 August 2014 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today reports its interim results for the six months ended 30 June 2014.

Hikma delivers excellent first half results with 16% revenue growth and 44% increase in adjusted EPS

London, 20 August 2014 - Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today reports its interim results for the six months ended 30 June 2014.

H1 2014 highlights

Group

  • Group revenue increased by 16% to $738 million, driven by the very strong performance of our Injectables business in the first half
  • Group adjusted operating margin rose to 33.2%, up from 29.6%, reflecting a higher Injectables margin
  • Profit attributable to shareholders increased by 132% to $169 million. On an adjusted basis, profit attributable to shareholders rose 44% to $176 million
  • Basic EPS increased 130% to 85.4 cents per share
  • Net cash flow from operating activities increased by $64 million to $200 million
  • Completed the acquisition of assets of Bedford Laboratories ("Bedford") in July 2014 and agreed to acquire substantially all of the assets of the Ben Venue manufacturing site, significantly enhancing the long term strength of our global Injectables business
  • Continued to build our global product portfolio through new product introductions across all countries and markets – launched 49 products and received 140 product approvals
  • Interim dividend of 7.0 cents per share, in line with the first half of 2013
  • Declared a special dividend of 4.0 cents per share, reflecting the exceptionally strong market opportunities captured by our US businesses in the first half of 2014

Branded

  • Good performances across most markets, with strong growth in key markets such as Egypt and Saudi Arabia
  • Lower than expected sales in Algeria due to restructuring and in Sudan, Iraq and Libya due to escalating political disruptions
  • Branded revenue grew by 1% and adjusted operating profit decreased by 9%, with adjusted operating margin of 20.8%, compared with 23.0% in the first half of 2013
  • Branded business is now expected to deliver low single digit revenue growth for the full year, resulting in an adjusted operating margin below full year 2013

Injectables

  • Global Injectables revenue grew 41%, with an adjusted operating margin of 41.0%
  • Excellent performance in the first half, driven by strong underlying growth in the US, enhanced by specific market opportunities
  • Continue to expect Injectables revenue growth above 20% for the full year, reflecting the weighting of sales towards the first half, and adjusted operating margin of around 35% for the full year, before the slight dilution from Bedford

Generics

  • Continued benefit from specific market opportunities and the re‐introduction of products drove Generics revenue of $128 million, a decrease of only 3%
  • Generics adjusted operating profit was $79 million compared with $82 million in the first half of 2013, with an adjusted operating margin of 61.7%
  • We now expect full year revenue to be around $200 million, with an adjusted operating margin of above 45%

Said Darwazah, Chief Executive Officer of Hikma, said:

“I am very pleased with our first half results, which reflect strong underlying performances in our businesses and our success in capturing a number of specific market opportunities.

In the MENA region, our focus on new, higher value products is delivering good results in key markets. Whilst this is being offset by weakness in other markets this year, our businesses across the region remain well positioned to drive future growth. Our Injectables business delivered an excellent performance, as we captured a number of attractive market opportunities. I am delighted we have acquired the Bedford assets, which will add products, R&D capabilities and capacity to support future growth for the global Injectables business. Our Generics business is performing extremely well and we are working hard to strengthen the product portfolio and pipeline.

Over the past eighteen months the Group has generated significant cash flows and our strong balance sheet is enabling us to make strategic investments across our businesses. Overall, the Group is benefiting from our diversified business model and I am pleased to be reiterating our Group guidance of around 5% revenue growth for the full year.”

Group financial highlights

Summary P&L
$ million
H1 2014 H1 2013 Change
Revenue 738 638 +16%
Gross profit 441 353 +25%
Gross margin 59.8% 55.3% +4.5pp
       
Operating profit 236 143 +65%
Adjusted operating profit1 245 189 +30%
Adjusted operating margin 33.2% 29.6% +3.6pp
       
EBITDA2 269 182 +48%
       
Profit attributable to
shareholders
169 73 +132%
       
Adjusted profit attributable to
shareholders1
176 122 +44%
       
Basic earnings per share (cents) 85.4 37.1 +130%
Adjusted basic earnings per share (cents)1 88.9 61.9 +44%
       
Dividend per share (cents) 7.0 7.0 --
Special dividend per
share (cents)
4.0 3.0 +33%
Total dividend per
share (cents)
11.0 10.0 +10%
       
Net cash flow from operating activities 200 136 +47%

Enquiries:

Hikma Pharmaceuticals PLC  
Susan Ringdal, VP Corporate Strategy and Director of Investor Relations +44 (0)20 7399 2760/
+44 7776 477050
Lucinda Henderson, Deputy Director of Investor Relations +44 (0)20 7399 2765/
+44 7818 060211
FTI Consulting
Ben Atwell/ Matthew Cole/ Julia Phillips +44 (0)20 3727 1000

 

About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non‐branded generic and in‐licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2013, Hikma achieved revenues of $1,365 million and profit attributable to shareholders of $212 million.

A presentation for analysts and investors will be held today at 09:30 at FTI Consulting, 200 Aldersgate, Aldersgate Street London EC1A 4HD. To join via conference call please dial: +44 (0) 20 3003 2666 or 0808 109 0700 (UK toll free). Alternatively you can listen live via our website at www.hikma.com. A recording of both the meeting and the call will be available on the Hikma website. The contents of this website do not form part of this interim management report.

1Before the amortisation of intangible assets (excluding software) and exceptional items, as set out in note 4 to the condensed set of financial statements
2Earnings before interest, tax, depreciation and amortisation. EBITDA is stated before impairment charges and share of results from associated companies

Press Release
+ more
Print page

Corporate

07 August 2014

Notice of Interim Results Announcement – Analyst Presentation

London, 07 August 2014 – Notice of Interim Results Announcement 2014. A presentation and webcast for analysts will take place at 9:30am GMT at FTI Consulting, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD (please note NEW address).

Notice of Interim Results Announcement 2014. A presentation and webcast for analysts will take place at 9:30am GMT at FTI Consulting, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD (please note NEW address).

Wednesday 20 August 2014

9.30am (London time)/ 11.30am (Jordan time)

FTI Consulting, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD. (PLEASE NOTE NEW ADDRESS)

To join via conference call please dial: +44 (0) 20 3003 2666
UK Toll-Free Number: 0808 109 0700

Alternatively you can listen live via our website: www.hikma.com or www.cantos.com

Playback facility:
A playback of the conference call will be available via our website later that day on www.hikma.com

+ more
Print page

Corporate

24 July 2014

Hikma agrees to acquire Ben Venue manufacturing site adding R&D capabilities and capacity

London, 24 July 2014 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announces that it has agreed with Ben Venue Laboratories, Inc. ("Ben Venue"), part of the Boehringer Ingelheim Group of Companies, to acquire substantially all of the assets of their generic injectables manufacturing site in Bedford, Ohio. The acquisition is pursuant to the exclusivity arrangement entered into on 28 May 2014. No incremental consideration is payable in relation to Hikma acquiring the Ben Venue manufacturing site.

London, 24 July 2014 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announces that it has agreed with Ben Venue Laboratories, Inc. ("Ben Venue"), part of the Boehringer Ingelheim Group of Companies, to acquire substantially all of the assets of their generic injectables manufacturing site in Bedford, Ohio. The acquisition is pursuant to the exclusivity arrangement entered into on 28 May 2014. No incremental consideration is payable in relation to Hikma acquiring the Ben Venue manufacturing site.

The Ben Venue manufacturing site includes four manufacturing plants and a Quality and Development Centre ("QDC") with excellent capabilities.  The QDC, which includes a R&D pilot plant and a team of experienced employees, will significantly strengthen Hikma's existing R&D capabilities, support the development of a strong future pipeline and expedite the transfer and reactivation of recently acquired ANDAs.

All manufacturing at the Ben Venue site was ceased in December. Over time, Hikma will evaluate the potential to partially reactivate the site to support the delivery of its medium and long term growth plans. In the short term, Hikma will transfer certain modern, advanced equipment, including lyophilisers and filling lines, to its other global manufacturing facilities in the US and Europe, significantly increasing its current injectable manufacturing capacity and capabilities.

The gross assets subject to the transaction, prior to the performance of the fair value exercise and excluding acquired intangible assets, have a book value of $4 million.1 The acquisition of the Ben Venue manufacturing site is subject to customary approvals in the United States.

The guidance previously provided on 28 May 2014 remains unchanged. The acquisition of assets of Bedford, including the Ben Venue site, is expected to be slightly dilutive to adjusted2 earnings per share in 2014 and 2015 and strongly accretive to adjusted earnings per share from 2016 onwards.

Said Darwazah, Chairman and Chief Executive Officer of Hikma commented:
"I am very pleased to be acquiring the Ben Venue manufacturing site and their talented R&D team. We believe this will meaningfully enhance our R&D capabilities and enable us to significantly expand future capacity. This reflects Hikma's commitment to the long term growth of our fast growing global Injectables business and will create significant strategic value.”

--  ENDS  --

1 The book value of the gross assets in the financial statements of Ben Venue Laboratories, Inc at 31 December 2013
2 Before the amortisation of intangibles (excluding software)

Enquiries

Hikma Pharmaceuticals PLC  
Susan Ringdal, VP Corporate Strategy and Director of Investor Relations +44 (0)20 7399 2760/
+44 7776 477050
Lucinda Henderson, Deputy Director of Investor Relations +44 (0)20 7399 2765/
+44 7818 060211
FTI Consulting  
Ben Atwell/ Matthew Cole/ Julia Phillips +44 (0)20 3727 1000

About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: “Branded”, “Injectables” and “Generics”, based principally in the Middle East and North Africa ("MENA"), where it is a market leader, the United States and Europe. In 2013, Hikma achieved revenues of $1,365 million and profit attributable to shareholders of $212 million.

+ more
Print page

Corporate

Get adobe reader Most computers will open PDF documents automatically, but you may need to download Adobe Reader.